↓ Skip to main content

Peanut oral immunotherapy in adolescents: study protocol for a randomized controlled trial

Overview of attention for article published in Trials, April 2015
Altmetric Badge

Mentioned by

twitter
1 X user
patent
3 patents

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
62 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Peanut oral immunotherapy in adolescents: study protocol for a randomized controlled trial
Published in
Trials, April 2015
DOI 10.1186/s13063-015-0717-y
Pubmed ID
Authors

Elodie Michaud, Bertrand Evrard, Bruno Pereira, Emmanuelle Rochette, Lise Bernard, Paul-Olivier Rouzaire, Nelly Gourdon-Dubois, Etienne Merlin, Jean-Luc Fauquert

Abstract

Peanut allergy is an increasingly common health problem. Current treatment guidelines are based on strict avoidance. However, in the last few years, oral immunotherapy protocols have shown promising results yielding increased tolerance to peanut in allergic children. Adolescence is particularly at risk. We have designed a randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of peanut oral escalating immunotherapy in a 12- to 18-year-old population with proved allergy to peanut. Patients are selected when the threshold of peanut intake is over 100 mg and 2 cumulated g on the first double-blind, placebo-controlled oral food challenge (DBPCOFC). During the build-up placebo-controlled blinded phase, doses containing peanut or placebo will be administered by gradual up-dosing from 10 mg to 2 g with 2-weekly increments. After this first randomized phase, the desensitized participants will continue to intake native peanut in an unblinded process during 13 or 37 weeks following a second randomization. Adverse events are picked up and managed throughout the entire protocol. The main endpoint is the percentage of patients with negative DBPCOFC at the threshold of 2 g of cumulative peanut at the end of the build-up phase of 24 weeks. Secondary endpoints include: (1) desensitization 6 weeks and 6 months after the end of the maintenance phase; (2) adverse effects during the build-up phase; (3) immunological profile confirming peanut desensitization. Immunologic assays will be carried out at every DBPCOFC and at the middle of the build-up phase to evaluate the peanut immunologic profile modifications. This double-blind, placebo-controlled study will be, to our knowledge, the first evaluation of a peanut oral immunotherapy protocol in teenagers in the purpose to reduce severe reactions after unexpected intake and to improve quality of life. ClinicalTrial.gov: NCT02046083 (23 January 2014).

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 62 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 2%
France 1 2%
Unknown 60 97%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 10 16%
Other 9 15%
Researcher 8 13%
Student > Ph. D. Student 7 11%
Student > Master 6 10%
Other 7 11%
Unknown 15 24%
Readers by discipline Count As %
Medicine and Dentistry 16 26%
Nursing and Health Professions 10 16%
Pharmacology, Toxicology and Pharmaceutical Science 6 10%
Psychology 3 5%
Agricultural and Biological Sciences 2 3%
Other 8 13%
Unknown 17 27%